Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAQUALITY infliximab for moderate to severe psoriasis
2005-004465-41Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in psoriasis, sponsored by Merck & Co. Primary endpoint: PASI 75 response rate at week 10. Started Mar 2006; status: completed.
02
Drugs
infliximab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2005-004465-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004465-41.